U

Ultromics

www.ultromics.com link_icon

Ultromics Market Research Report



Company Overview



  • Name: Ultromics Limited


  • Mission: Ultromics is committed to using artificial intelligence to build solutions that address unmet needs in cardiovascular medicine, specifically focusing on early and accurate detection of heart failure.


  • Founded: 2017


  • Founders: Dr. Ross Upton and Prof. Paul Leeson


  • Key People:

  • Dr. Ross Upton, Founder and Chief Executive Officer

  • Prof. Paul Leeson, Founder and Chief Medical Officer

  • John Russell, Chairman

  • Dr. Helen Routh, Non-Executive Director

  • Amir Hasan, Chief Operating Officer

  • Dr. Gary Woodward, Chief Product Officer

  • Roger Owens, Chief Commercial Officer

  • Dr. Nancy Spagou, Chief Experience Officer

  • Dr. Jaco Jacobs, Chief Regulatory and Compliance Officer


  • Headquarters: Oxford, United Kingdom


  • Number of Employees: No information is available


  • Revenue: No information is available


  • Known For: Ultromics is known for its AI-powered heart failure detection technology, particularly its EchoGo platform, which significantly improves the diagnosis of heart failure with preserved ejection fraction (HFpEF).




Products



  • EchoGo Heart Failure

  • Description: A state-of-the-art AI-driven solution used in cardiac examinations to detect HFpEF using echocardiography.

  • Key Features:

  • AI automation that integrates with any vendor in any care setting.

  • Detects HFpEF with precision using a single apical four-chamber echocardiogram view.

  • FDA-cleared, cloud-native architecture for optimal resource use.

  • Provides quick analysis with report generation within 30 minutes.

  • Reduces indeterminate diagnosis cases significantly, thus aiding better treatment pathways.

  • Improves diagnostic accuracy by 90% compared to traditional clinical algorithms.




Recent Developments



  • New Products Launched: EchoGo Heart Failure, with ongoing development of algorithms for other forms of cardiac dysfunction, like cardiac amyloidosis.


  • Recent Studies and Research:

  • A study confirming the link between AI-based HFpEF detection and cardiac outcomes, published in July 2024.

  • Ongoing partnership with the Foundation for the National Institutes of Health (FNIH) under the AMP Heart Failure initiative.


  • New Features Added: Expedited interpretation of echocardiograms using AI, streamlining diagnosis processes.


  • New Partnerships:

  • Collaboration with Mayo Clinic to enhance echocardiographic datasets for AI learning.

  • Partnered with Johnson & Johnson Innovative Medicine for advancements in cardiac amyloidosis detection.

  • Engaged in collaborations with organizations like FNIH to develop AI solutions for heart failure detection.




Recent Achievements and Recognition



  • Awards and Recognition:

  • FDA Breakthrough Device Designation for AI applications in cardiac amyloidosis and HFpEF.

  • Winner of Best Emerging Medtech Company at the OBN Awards 2022.


  • Key Partnerships:

  • Collaboration with healthcare providers including Mayo Clinic, Northwestern University, and City of Hope.

  • Partnership with Microsoft Azure for cloud-based echocardiography services.


  • Innovative Growth:

  • Secured $33 million in a Series B funding round led by Blue Venture Fund, with contributions from Optum Ventures and Google Ventures.


  • Clinical and Regulatory Milestones:

  • FDA clearance for multiple AI applications.

  • Clinical trials and validations across various healthcare sites worldwide, including involvement with the NHS.




This report summarizes Ultromics' position as an innovative leader in AI-driven solutions for cardiovascular medicine, revolutionizing heart failure detection and improving patient care through strategic partnerships and cutting-edge technology development.